ProQR Therapeutics N.V.
PRQR
$1.47
-$0.06-3.92%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.33M | 5.46M | 3.37M | 4.33M | 4.76M |
| Total Other Revenue | -- | 32.60K | 38.60K | 179.30K | 233.60K |
| Total Revenue | 2.33M | 5.49M | 3.41M | 4.51M | 4.99M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2.33M | 5.49M | 3.41M | 4.51M | 4.99M |
| SG&A Expenses | 4.42M | 4.53M | 3.65M | 5.47M | 3.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.00M | 16.08M | 16.60M | 18.41M | 16.37M |
| Operating Income | -15.66M | -10.59M | -13.19M | -13.90M | -11.38M |
| Income Before Tax | -15.36M | -10.38M | -12.87M | -13.80M | -10.61M |
| Income Tax Expenses | -- | 1.20K | -- | 20.40K | -- |
| Earnings from Continuing Operations | -15.36M | -10.38M | -12.87M | -13.82M | -10.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.36M | -10.38M | -12.87M | -13.82M | -10.61M |
| EBIT | -15.66M | -10.59M | -13.19M | -13.90M | -11.38M |
| EBITDA | -14.87M | -10.33M | -12.41M | -13.14M | -10.67M |
| EPS Basic | -0.15 | -0.10 | -0.12 | -0.13 | -0.10 |
| Normalized Basic EPS | -0.09 | -0.06 | -0.08 | -0.08 | -0.06 |
| EPS Diluted | -0.15 | -0.10 | -0.12 | -0.14 | -0.11 |
| Normalized Diluted EPS | -0.09 | -0.06 | -0.08 | -0.08 | -0.06 |
| Average Basic Shares Outstanding | 105.36M | 105.35M | 105.35M | 105.34M | 105.30M |
| Average Diluted Shares Outstanding | 105.36M | 105.35M | 105.35M | 105.34M | 105.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |